GPR183 and cancer: Importantly, it also inhibits oxysterol-induced cell migration and EBI2-induced cell proliferation 8,9 and thus establishes a clinical relevance of EBI2 antagonists in various inflammatory diseases and in EBV-mediated cancers, where EBI2 may be involved (see below).